Clinically relevant antimicrobial resistant bacteria, genetic resistance elements, and antibiotic residues (so-called AMR) from human and animal waste are abundantly present in environmental samples. This presence could lead to human exposure to AMR. In 2015, the World Health Organization (WHO) developed a Global Action Plan for Antimicrobial Resistance with one of its strategic objectives being to strengthen knowledge through surveillance and research. With respect to a strategic research agenda on water, sanitation and hygiene and AMR, WHO organized a workshop to solicit input by scientists and other stakeholders. The workshop resulted in three main conclusions. The first conclusion was that guidance is needed on how to reduce the spread of AMR to humans via the environment and to introduce effective intervention measures. Second, human exposure to AMR via water and its health impact should be investigated and quantified, in order to compare with other human exposure routes, such as direct transmission or via food consumption. Finally, a uniform and global surveillance strategy that complements existing strategies and includes analytical methods that can be used in low-income countries too, is needed to monitor the magnitude and dissemination of AMR.
METHODS
During the workshop 'Developing a Research Agenda for Water, Sanitation and Hygiene (WaSH) and Antimicrobial resistance (AMR)', input from the scientific community of water professionals was solicited on the role of the environment in the spread of AMR, mostly antibiotic resistance, and possible adverse health outcomes of environmental exposures in order to identify knowledge gaps and to develop a research agenda for WaSH aspects of AMR. Key issues in risk assessment, risk management, and monitoring and surveillance were discussed. This research agenda aims to identify knowledge gaps that need to be addressed in order to achieve the WaSH-related objectives (objectives 1-3, see Box 1) of the GAP on AMR and can thus be a foundation for future global guidance and action on WaSH and AMR.
The program started with several presentations on the latest insights regarding AMR and WaSH from both health and environmental perspectives. During breakout sessions, the participants were divided into three groups to consider questions on the following topics:
• risk assessment • risk management • monitoring and surveillance.
RESULTS
Prof. Dr Ana Maria de Roda Husman of the National Institute of Public Health and the Environment (RIVM) of the Netherlands opened the discussion on the importance of AMR in the environment. The complex interaction of the natural environment, i.e., water, soil, and air (Huijbers et al. ) , and the interplay of AMR bacteria, AMR genes, and antibiotic residues in the environment were highlighted. AMR originates from humans and animals exposed to antibiotics, and from the environment itself; thus, AMR should be approached as a The WHO has led the development of a GAP that reflects the commitment, perspectives, and roles of all relevant stakeholders, and in which everyone has clear and shared ownership and responsibilities. The action plan is built on six guiding principles: public and stakeholder engagement, actions based on best available knowledge and evidence, 'prevention first', 'access not excess', sustainability, and incremental targets for implementation.
Furthermore, a briefing note on AMR in the environment was prepared (WHO b). Abebe discussed the purpose of the review, which is to evaluate the role of environmental exposure to AMR bacteria and human health outcomes through evaluating the methods used to create the linkages. Expected outcomes from the review will be an assessment of methods used to create environmental linkages between transmission of AMR bacteria in environmental and human reservoirs to human health outcomes to identify gaps, and thereby make recommendations for establishing stronger evidence for links between environmental exposure to AMR bacteria and adverse human health outcomes. This work will lead to a literature review that focuses on AMR and WaSH from an integrated One Health perspective, and it is envisaged that this will serve to stimulate a research agenda on AMR and 
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Risk assessment
During this breakout session, facilitated by Prof. Dr Antoine Andremont, the following questions were asked of the participants:
• What are the needs to identify and quantify the sources, occurrence, and transport of AMR bacteria and their genes?
• What are the needs to estimate risk of AMR bacteria to human health?
Multiple studies (references were made by participants to studies conducted in Germany, New Zealand, Australia, Denmark, the UK, the Netherlands, Thailand, and South Africa) have been carried out on the identification of antibiotic (AB) residues, and AMR bacteria and AMR genes throughout the water cycle as well as certain 'hotspots' such as hospital wastewater systems, biogas plants, wastewater treatment plants, and livestock such as poultry (New Zealand). The monitoring data now available are insufficient to identify occurrence status and trends in the appearance of AMR. It is clear, however, that AMR is found throughout the pathways from human and animal to excreta and manure, but it is more difficult to identify and quantify these conditions in the other domains of the water cycle. Research is needed on the selection of bacteria, AMR properties, locations, sample matrices, and standardized analytical methods for monitoring. The HACCP approach (Hazard Analysis and Critical Control Points) could be a useful method to identify the 'critical control points', bacterial analytical methods, and matrices. Water Safety Plans and Sanitary Safety Plans are primarily based on this approach. It is important to find the most important pathways, whether these be drinking water or other environmental exposure pathways and media, e.g., irrigation with wastewater. This knowledge would help to inform the public and other stakeholders on effective measures.
There is discussion on the importance of water as a pathway for AMR compared to other exposure routes, such as food or from person to person. However, this does not mean that inadequate sanitation and fecally contaminated water could not be important routes for AMR transmission.
Little is known about exposure to AMR through WaSH routes and the resulting effects on public health. Therefore, research is needed in this field. So far, experiments to transfer genes in laboratory simulations have not succeeded.
The potential risk of infection by AMR bacteria through the consumption of drinking water gives rise to the public's questions and concern. This is especially a concern in areas in which water reuse projects are being developed and implemented. Governments and water companies need to address these questions supported by scientific data that are based on actual evidence of exposure and observed health risks. It is important that these data are collected in a transparent way with good study design and methods, allowing for easy comparison with studies in other countries or regions. Research is needed to develop these approaches.
Risk management
During this breakout session, facilitated by Prof. Dr Ana Maria De Roda Husman, the following questions were asked of the participants:
• What are the needs with regard to water and wastewater treatment technologies?
• What are the needs with regard to practical risk manage- In terms of water and wastewater technology applications, three dominant questions centered on identifying basic mass balance inputs:
• What levels of AMR bacteria, genetic material, or antibiotic residues are entering the treatment system?
• What levels are removed or could potentially be removed?
• What levels in effluent and biosolids are necessary to protect the receiving environment and ultimately benefit the clinical settings?
With regard to answering these questions, the group noted that studies have been undertaken on the occurrence of AMR bacteria, AMR genes, and antibiotic residues in raw sewage, although, not using a standardized methodology.
Moreover, quantitative information is needed on potential environmental concentrations; loading mass/volume; and total load in animals, agriculture, wildlife, household, and Research into treatment technologies should also consider low-cost technologies, appropriate developing world technologies, conventional treatment (water and wastewater), non-standard techniques such as solar/sunlight, and septic systems with/without reticulated water supply.
There is a need for criteria and guidelines to assess technologies in order to assist policymakers and utility managers in identifying appropriate technologies and their performance capabilities.
To address the third dominant question, the group noted that treatment requires a goal. How much removal is necessary to make a difference in controlling ARM impacts on the environment and human health? What levels in the environment are acceptable with regard to public health protection?
How can we work to quantify health impacts associated with reductions in drug usage or drug concentrations (will reducing drug usage have negative health impacts)? What are the health impacts associated with AMR bacteria or genes and loading to the environment, that is, will reducing AMR bacteria or genes loading to the environment improve Identification and quantification of sources, occurrence, and transport (contributes to GAP-objective no. 2):
• Quantify concentrations and total loads of AMR bacteria, AMR genes, and antibiotic residues from humans and animals to the environment.
• Identify and quantify AMR bacteria, AMR genes, and antibiotic residues in different water-related exposure routes and determine the importance of each route in order to focus research capacity and to support guidance and advice to stakeholders and the public on adequate actions. Identify, quantify, and locate in time and space the sources that are hotspots of release such as health care facilities.
• Set up a uniform system and methodology for identification and quantification (HACCP as a suggested approach). • Perform meta-analysis to determine and quantify the persistence of AMR bacteria, AMR genes, and antibiotic residues in different environmental matrices.
• Determine the occurrence, loads, and persistence of AMR bacteria, AMR genes, and antibiotic residues in the environment.
Understanding the risk to human health (contributes to GAP-objective no. 2):
• Identify health impacts associated with reductions in drug usage or drug concentrations. • Identify health impacts associated with ARB/ARGAMR bacteria and gene concentrations and loading to the environment.
• Conduct risk assessment strategies to identify acceptable environmental concentrations or acceptable biological entities (i.e., certain bacteria or genes are acceptable whereas others are not) in exposure media such as water.
• Determine concentrations or loads (in wastewater effluent and biosolids) that are necessary to protect the receiving environment and ultimately benefit the clinical settings.
Efficiency of water and wastewater treatment technologies (contributes to GAP-objective no. 2 and 3):
• Provide criteria and guidance on waste and wastewater management for the reduction of AMR bacteria, AMR genes, and antibiotic residues in relevant settings, e.g., clinical, agricultural, household, and the environment.
• Quantify the role of AMR horizontal gene transfer in waste and wastewater. • Identify ways of optimizing onsite waste treatment for reduction of AMR bacteria, AMR genes, and antibiotic residues.
• Address exposure risks by determining reduction efficiencies of applied water, waste treatment and human and animal excreta treatment processes for AMR bacteria, AMR genes and antibiotic residues and other WaSH-related settings and facilities, including household water treatment processes, water reuse practices and alternative sanitation systems.
• Identify simple microbial measurements (such as bacterial indicators) for system verification.
• Incorporate AMR bacteria, AMR genes and antibiotic residues in WHO Water Safety Plans and Sanitation Safety Plans, programs and practices. Identify critical control points to utilize in such Safety Plans.
• Develop criteria and guidance to water utilities, wastewater treatment plants and other AMR-relevant treatment facilities (antimicrobial production and aquaculture facilities) on the reduction efficiencies of their applied treatment processes and overall treatment for AMR bacteria, AMR genes and antibiotic residues.
• Develop criteria and guidance to different communities such as rural communities on the reduction efficiencies of AMR bacteria, AMR genes and antibiotic residues by local waste and wastewater practices and processes. From the discussion, three major themes could be identified, which are discussed here.
Evidence of water as a pathway for AMR exposure
The importance of water, wastewater, and wastes as pathways for AMR human exposure (compared to other routes such as food consumption) was identified as a research focus (see also the review by O'Neill ()). Little is known about the exposure to AMR through WaSH routes, drinking water consumption, and water reuse applications and resulting effects on public health. Data based on magnitudes of exposure and objectively measurable health outcomes should be collected in a consistent and transparent way, to achieve data comparability among countries or regions, respecting the basic principles for the 'right to data'.
Guidelines for a consistent and pragmatic approach to prevention and control
There is a need for a pragmatic approach to make prevention and control of AMR actionable, accessible, and Box 2 | Continued.
Development of practical risk management systems and tools (contributes to GAP-objective no. 1):
• Develop, exchange and link information, data and experiences from the environmental domain to industrial, clinical and veterinary domains and vice versa (including epidemiological information).
• Identify target communities such as septic tank communities in rural settings as well as health care facilities and their professionals (e.g., nurses) and educational institutions (schools and their teachers) in clinical, educational and rural settings to raise awareness of proper treatment or handling of waste and wastewater for awareness raising on what to do with waste and wastewater and AMs with respect to AMR and produce and implement community specific educational materials.
• Collect and provide evidence-based information to the public on safety of drinking water and wastewater used in agriculture and aquaculture with respect to AMR.
Identification of policies, practices and tools (contributes to GAP-objective no. 1 and 3):
• Perform systematic reviews of the literature on regional/national policies and risk governance for AMR.
• Determine effectiveness of regulations not specifically directed at reduction of AMR bacteria, AMR genes and antibiotic residues and develop indicators for monitoring of policy and practice measures related to AMR.
• Derive treatment targets (Log Reduction Values) and other health health-based targets in relevant media (water, wastewater, biosolids, etc.) for exposure to AMR bacteria, AMR genes and antibiotic residues to determine the need for reduction.
Development of monitoring strategies, surveillance and regulatory agents (contributes to GAP-objective no. 3):
• Provide criteria and guidance for the different purposes, targets and methods of AMR surveillance and monitoring (using a tiered and preferably holistic approach), interpretations of AMR data and actions to be taken.
• Select index parameters and standard analytical methods to identify and quantify AMR bacteria, genes and residues in the relevant environmental media that are applicable in low resource settings too. 
Uniform and global surveillance
The call for a consistent, pragmatic, and transparent approach is also reflected in the use and harmonization of surveillance and monitoring techniques and the call for criteria and guidelines. Methods that can be used in all countries, including those with limited resources, should be identified, validated, and implemented to monitor AMR in the environment. The sampling methods should be those already in use to survey the bacterial concentrations and loads in the environment. The simplest would be to add screening to quantify a single type of AMR bacteria as a minimal requirement in these samples. ESBL-E. coli appears to be a relevant candidate because: (i) it is easily detected using commercial media and screening plates used in human medicine; (ii) large variations in occurrence and densities that are to be expected between countries can be quantified; and (iii) it could be a monitoring system common across human medicine, the food chain, and water and wastewater management, thus allowing powerful geographical comparisons and follow-up over time.
CONCLUSIONS
Understanding and addressing the role of WaSH in combatting AMR is a critical element of the GAP on AMR.
Therefore, research and development of guidance under the three previously identified themes is needed:
• to identify and quantify the sources, occurrence and transport of antibiotics, other antimicrobial agents and their metabolites, AMR bacteria, and AMR genes in environmental media, especially water, wastewater, animal fecal wastes and biosolids and other media to which humans are exposed;
• to understand the human health outcome from environmental exposures;
• to identify water and waste treatment technologies that can remove antibiotics and other antimicrobial agents, their metabolites, AMR bacteria, and AMR genes in human animal wastes and in environmental media for which the WHO provides specific guidance;
• to identify options to minimize the release or introduction of antibiotics and other antimicrobial agents, AMR bacteria, and AMR genes into the environment by the establishment and use of policies, programs, and practices to eliminate and minimize use and to contain or destroy these contaminants at their source or 'critical control points';
• to identify policies, practices, and tools to minimize human exposure to AMR from the environment;
• to support and develop monitoring strategies, surveillance and regulatory activities for AMR prevention and control related to the environment and WaSH. they do not necessarily represent the views, decisions or policies of WHO.
